Acadia Pharma (NASDAQ: ACAD) reported Q3 EPS of ($0.40), $0.05 better than the analyst estimate of ($0.45). Revenue for the quarter came in at $211.7 million versus the consensus estimate of $192.2 million.

For FY23 the company guides:

• NUPLAZID net sales in the range of $537.5 to $545 million.
• R&D expense in the range of $340 to $350 million.
• SG&A expense in the range of $390 to $400 million

For earnings history and earnings-related data on Acadia Pharma (ACAD) click here.